Stable management, increasing product portfolio, robust international retail presence, multiple international warehouses, unquestioned technology lead, thumbs up from Cochlear, US OTC pending, generating great start-up cash flow.
I have no issue with issuing performance options to staff, exercisable at higher future prices...win win buddy.
Auditor statement is dime a dozen for junior ASX companies. The market has absorbed the 3B, market cap is higher, dilution minimal, key staff retained.
Add to My Watchlist
What is My Watchlist?
